Invention Grant
US08829159B2 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
有权
用于胰腺导管腺癌检测和治疗的Plectin-1靶向药物
- Patent Title: Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
- Patent Title (中): 用于胰腺导管腺癌检测和治疗的Plectin-1靶向药物
-
Application No.: US12937777Application Date: 2009-04-14
-
Publication No.: US08829159B2Publication Date: 2014-09-09
- Inventor: Kimberly Kelly , Ralph Weissleder , Nabeel Bardeesy
- Applicant: Kimberly Kelly , Ralph Weissleder , Nabeel Bardeesy
- Applicant Address: US MA Boston
- Assignee: The General Hospital Corporation
- Current Assignee: The General Hospital Corporation
- Current Assignee Address: US MA Boston
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2009/040480 WO 20090414
- International Announcement: WO2009/129220 WO 20091022
- Main IPC: C07K7/06
- IPC: C07K7/06 ; C07K7/08 ; A61K38/08 ; A61K38/10 ; A61K49/00 ; B82Y5/00 ; A61K47/48 ; G01N33/533 ; G01N33/574 ; G01N33/531 ; A61K49/18 ; A61K38/00
Abstract:
Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
Public/Granted literature
- US20110182814A1 PLECTIN-1 TARGETED AGENTS FOR DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA Public/Granted day:2011-07-28
Information query
